MADRIGAL PHARMACEUTICALS, INC. 8-K

What Happened
Madrigal Pharmaceuticals, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2025 via a press release dated February 19, 2026. The company furnished that press release as Exhibit 99.1 to the Current Report on Form 8‑K filed February 19, 2026. The report was signed by Mardi Dier, Executive Vice President and Chief Financial Officer.

Key Details

• Press release announcing results dated February 19, 2026 and furnished as Exhibit 99.1 to the 8‑K.
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Form 8‑K was signed by Mardi Dier, EVP & CFO, on February 19, 2026.
• The company notes the information and Exhibit 99.1 are furnished (not “filed”) for purposes of Section 18 of the Exchange Act.

Why It Matters
This 8‑K notifies investors that Madrigal has publicly released its latest quarterly and full‑year financial results; those details (revenue, net income/loss, operating metrics, and any management commentary or guidance) will be in the attached press release. Retail investors should review the Exhibit 99.1 press release and follow subsequent SEC filings (e.g., Form 10‑K or earnings slides) for audited figures and additional context that could affect the stock.